Skinvisible, Inc. (SKVI)

Our latest clients all have the potential to grow significantly in the near and long-term future

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Dec 21, 2017 6:58 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) May Target Booming Pain Management Market Through Proposed Merger with Quoin Pharmaceuticals

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) recently signed a Letter of Intent (“LOI”) regarding a proposed merger with Quoin Pharmaceuticals Limited. The potential partnership could target significant unmet medical needs on the pain management market. An article discussing this reads: “Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even larger. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.”

To view the full article, visit: http://nnw.fm/8dFiK
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Dec 28, 2017 4:57 pm

Skinvisible, Inc. (SKVI) and Quoin Poised to Tackle Opioid Crisis with Alternative Pain Therapies

- A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies
- The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management
- Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start

A recent article by the Washington Post (http://nnw.fm/ikb1U) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than originally thought. The story alludes to the possibility that “drug manufacturers and distributors turned a willfully blind eye toward illegal drug trafficking.” In the midst of this, there is an opioid epidemic that has been deemed a national health emergency that results in 90 deaths per day (http://nnw.fm/V60zK) and is growing exponentially, according to the Centers for Disease Control and Prevention.

There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed merger, with expected completion in early 2018, that will result in a new entity, Quoin Pharmaceuticals Inc. Upon completion of this merger, the new company (combining Quoin’s strengths of pharmaceutical development and Skinvisible’s innovative technologies that enhance delivery and product performance) has tremendous potential to address the significant needs of the pain management market.

One of the main areas of Quoin’s focus is to disrupt the opioid market (currently estimated at $6 billion annually in the U.S. alone) and produce and deliver to market non-opioid products that serve as effective and viable alternatives for the immense pain management market. This focus will include all areas of pain management, including critical needs in the post-surgical setting. At least 50 million U.S. surgeries require the use of post-operative pain management pharmaceuticals annually, and it is in the post-surgical setting that about 50 percent of opioid addictions begin.

To address the critical demands for effective alternatives to opioids, Quoin will launch one of its first lead products, QRX001, for effective treatment of post-surgical pain. The product, a transdermal NMDA receptor antagonist, delivers up to 72 hours of effective post-surgical pain relief. With the aim of providing alternatives to opioids as well as opiates, numerous clinical studies on QRX001 have shown that sub-anesthetic doses have resulted in a marked 24-hour reduction in PCA morphine consumption. In addition, clinical tests of the NMDA receptor antagonist generated superior results to any single existing product or combination and resulted in mild or absent adverse events, reduced post-surgical nausea and vomiting and reduced pain intensity.

With completion of the merger of Skinvisible and Quoin expected in early 2018, the synergies of the merged technologies, expertise and proven track records poise the new Quoin Pharmaceuticals with tremendous potential to address the needs of the immense pain market and tackle the opioid epidemic head-on.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Dec 29, 2017 4:49 pm

Skinvisible, Inc. (SKVI) Partnership with Quoin Focuses on Population’s Pain Needs

- Non-binding proposed merger announced on November 27, 2017
- Quoin merger expected to deliver non-opioid relief to post-surgical patients
- Over-65 population with advanced pain needs expected to double within next 30 years
- Skinvisible and Quoin proposed merger expected to deliver better results to patients

Health professionals are preparing for an expected doubling of the 65 years and older population within the next 30 years, creating medical need to address the pain that often becomes a prevalent companion to age. While modern pharmaceuticals have developed opioids and non-steroidal therapies for reducing chronic pain, the drugs are often accompanied by addiction and unwanted side effect concerns. However, Skinvisible, Inc.’s (OTCQB: SKVI) recently announced non-binding merger with Quoin Pharmaceuticals Limited is creating a partnership that may provide alternative solutions at a time when they are needed the most.

Quoin’s products include QRX001, which will provide 72 hours of effective non-opioid pain relief to post-surgical patients, and QRX002, which is an anticipated once-a-day solution for military PTSD patients at risk for suicidal tendencies. QRX001 will be formulated with an NMDA receptor antagonist that has undergone almost 30 pre-clinical trial studies in the United States. The studies have shown that sub-anesthetic doses of the compound reduced morphine consumption controlled by the patient, as well as post-operative nausea and the reported intensity of pain, while adverse events were reportedly mild or non-existent. QRX001 is anticipated to undergo a phase II trial in the coming year.

Leveraging these results, Skinvisible and Quoin hope to help reduce the abuse of prescription painkillers, which has received classification as a national health emergency (http://nnw.fm/5Nh0T). In a recent study reported in JAMA Surgery, 36,000 post-operative patients’ painkiller use was tracked over the course of a half year. The study found that five to six percent of the patients “continued to fill prescriptions for opioids long after what would be considered normal surgical recovery” (http://nnw.fm/K84Dc). In 2016, drug overdose deaths, the majority of them blamed on painkiller dependency, reportedly rose nearly 20 percent over those reported in 2015, according to the New York Times (http://nnw.fm/27Inj). The Centers for Disease Control and Prevention reported that opioid-related deaths quadrupled between 1999 and 2015 on par with a commensurate increase in the sale of prescription opioids to pharmacies and medical offices during that period (http://nnw.fm/V60zK).

“Pain is prevalent and often under-treated among older adults,” University of Texas at Arlington researcher Robert Gatchel said in a December statement to MD Magazine (http://nnw.fm/iUk9p). “With 20 percent of Americans expected to be 65 or older by 2030, the development of new and effective pain management strategies is a necessity, especially given that 75 percent of people in this age group have two or more chronic conditions such as heart disease, arthritis or diabetes, which complicate the taking of pain medications.”

The completion of the merger between Skinvisible and Quoin is subject to the negotiation of a definitive agreement and other customary closing conditions, including Quoin completing a financing round for clinical development.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Dec 29, 2017 5:04 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Prepares to Address Killer Drug Epidemic Through Proposed Merger Agreement

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) recently signed a letter of intent regarding a proposed merger with Quoin Pharmaceuticals Limited. The two companies intend to work together to address the opioid epidemic plaguing America. An article discussing this reads: “There are increased incentives and growing public and FDA/government demands to address the crisis. Innovators vying to meet critical needs and to combat the opioid issue with alternative, non-addictive and effective products include Skinvisible, Inc. (OTCQB: SKVI) and Quoin Pharmaceuticals Limited. As announced earlier this month, the two companies have entered a Letter of Intent for a proposed merger, with expected completion in early 2018, that will result in a new entity, Quoin Pharmaceuticals Inc. Upon completion of this merger, the new company (combining Quoin’s strengths of pharmaceutical development and Skinvisible’s innovative technologies that enhance delivery and product performance) has tremendous potential to address the significant needs of the pain management market.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Jan 05, 2018 6:28 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Could Create Non-opioid Pain Solution for Rising Population of Senior Citizens

Skinvisible (OTCQB: SKVI), a topical and transdermal product development company, recently entered a non-binding merger with Quoin Pharmaceuticals Limited. The two companies are expected to deliver a non-opioid solution to pain sufferers. An article discussing this reads: “Health professionals are preparing for an expected doubling of the 65 years and older population within the next 30 years, creating medical need to address the pain that often becomes a prevalent companion to age. While modern pharmaceuticals have developed opioids and non-steroidal therapies for reducing chronic pain, the drugs are often accompanied by addiction and unwanted side effect concerns. However, Skinvisible, Inc.’s (OTCQB: SKVI) recently announced non-binding merger with Quoin Pharmaceuticals Limited is creating a partnership that may provide alternative solutions at a time when they are needed the most.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Jan 08, 2018 6:04 pm

Skinvisible, Inc. (SKVI) Proposed Merger with Quoin to Provide 21st Century Cures

- Substance use disorder (SUD) has reached crisis proportions
- Deal links Quoin’s non-opioid analgesics to Skinvisible’s drug delivery system
- Market for opioids is currently about $6 billion annually

Opioids are killing Americans at an alarming rate. Every day ‘91 Americans die… from an opioid overdose’, according to the Centers for Disease Control and Prevention (CDC). In response to the substance abuse epidemic sweeping the nation, Congress passed the 21st Century Cures Act, which was signed into law by President Obama in December 2016. The legislation allocates over $1 billion to a variety of programs, some of which will attempt to wean patients away from addictive opium derivatives, a push unlikely to cause any degradation in pain management regimens. Non-opiates, in many instances, have proven to be just as effective for pain relief as oxycodone, hydrocodone or codeine, some widely used opioids. In October 2017, President Trump declared a public health emergency to deal with the opioid epidemic. Now that opioid use has reached crisis levels, bringing benign alternatives to market could rescue thousands from the perils of addiction. Skinvisible, Inc. (OTCQB: SKVI) plans to do exactly that. It is teaming up with Quoin Pharmaceuticals, in a proposed merger, to provide pain management products that, unlike opioids, do not provide a cure that is worse than the disease.

The abuse of opioids and other substances continues globally to be a vexing public health issue. The number of people reporting a substance use disorder (SUD) is on the rise, a development attributed to illicit opioids like heroin and opium but also, more alarmingly, to prescription opioid pain relievers (OPRs). The effects have been devastating. In 2015, 33,091 Americans died due to an accidental or unintentional opioid-related overdose. OPR abuse is largely responsible for the increase in SUD fatalities. ‘Deaths from prescription opioids—drugs like oxycodone, hydrocodone, and methadone—have more than quadrupled since 1999’, according to one CDC study (http://nnw.fm/Si7EU). This fourfold increase is in line with the volume of OPRs dispensed: ‘The amount of prescription opioids sold to pharmacies, hospitals, and doctors’ offices nearly quadrupled from 1999 to 2010’, a development that has been blamed on system failure (http://nnw.fm/wUc3k). There is, obviously, a pressing need for less pernicious painkillers. Luckily, there are indications that some non-opiates can be just as effective at reducing pain, as a recent study shows (http://nnw.fm/tbN2A).

Announcing the proposed merger with Quoin Pharmaceuticals Limited, Skinvisible provided an update on how it proposes to address this crisis (http://nnw.fm/Q4cye). The proposed first lead product, QRX001, is a single use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain. An NMDA receptor antagonist is a type of anesthetic that inhibits the action of the N-Methyl-D-aspartate receptor (NMDAR). Transdermal medicines are those applied to the surface of the skin that then penetrate into the blood stream. QRX001 is expected to provide up to 72 hours of effective analgesia post-surgically, eschewing the use of any opioid.

About half of those addicted were first introduced to opioids to combat pain after surgery. QRX001, when developed, may provide surgeons with a more effective alternative to opioids and to current opioid sparing products such as intravenous NSAIDs. The current market for opioids in the U.S. is estimated at $6 billion annually, and the highly differentiated nature of QRX001 could position it to capture significant market share either as a monotherapy or as part of multi-modal therapy. An application for Fast Track status for QRX001 will be filed.

The proposed merger with Quoin will allow Skinvisible to enter the post-surgical pain management market. The post-merger entity is expected to carry the name Quoin Pharmaceuticals Inc. and be listed on the OTCQB Venture Market.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Wed Jan 10, 2018 6:16 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) and Quoin Pharmaceuticals to Provide Opioid-free Pain Relief Solution

Topical and transdermal product development company Skinvisible (OTCQB: SKVI), through its recently entered non-binding merger agreement with Quoin Pharmaceuticals Limited, is planning to create a solution to the opioid crisis that is currently plaguing America. An article discussing this reads: “In response to the substance abuse epidemic sweeping the nation, Congress passed the 21st Century Cures Act, which was signed into law by President Obama in December 2016. The legislation allocates over $1 billion to a variety of programs, some of which will attempt to wean patients away from addictive opium derivatives, a push unlikely to cause any degradation in pain management regimens. Non-opiates, in many instances, have proven to be just as effective for pain relief as oxycodone, hydrocodone or codeine, some widely used opioids. In October 2017, President Trump declared a public health emergency to deal with the opioid epidemic. Now that opioid use has reached crisis levels, bringing benign alternatives to market could rescue thousands from the perils of addiction. Skinvisible, Inc. (OTCQB: SKVI) plans to do exactly that. It is teaming up with Quoin Pharmaceuticals, in a proposed merger, to provide pain management products that, unlike opioids, do not provide a cure that is worse than the disease.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Jan 19, 2018 6:52 pm

Proposed Merger Expands Skinvisible, Inc. (SKVI) Horizons into Multi-Billion Dollar Pain Market

- Company has developed and licensed novel drug delivery systems and products for over 15 years
- With 14 patents, Skinvisible has proven efficacy and global reach
- Proposed merger may transform non-opioid pain market

At the cutting edge of innovative drug delivery technology since 1999, Skinvisible, Inc. (OTCQB: SKVI), in a recently announced Letter of Intent of a proposed merger with Quoin Pharmaceuticals, is now expanding its horizons into the global pain management therapeutics market. The pain management therapeutics market is projected to expand at a 3.7 percent CAGR and exceed $83 billion in the United States by 2024 (http://nnw.fm/2GytJ). Skinvisible, through wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has already developed, licensed and sold multiple dermatology and health care products, as well as various medical treatments, using its patented Invisicare® technology. The proposed merger with Quoin Pharmaceuticals (http://nnw.fm/L6Fjc) would combine Skinvisible’s patented and proven novel drug delivery technologies that enhance the delivery of various active ingredients with Quion’s strong pharmaceutical background in post-surgical pain and promising approach to PTSD treatment.

Skinvisible has a long, successful history developing and licensing Invisicare®, its patented polymer technology. Enhancing how drugs are delivered on, in, or through the skin, Invisicare® has proven efficacy in a wide range of dermatology and health care products, including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis. Broad applications extend to sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations and, now, with a Quoin merger, the enhanced delivery of important non-opioid pain management medications.

With a focus on a lucrative licensing model and over 40 products developed in topical dermatology, Skinvisible has already achieved impressive market traction. The company offers a premium line of scientifically formulated, highly effective skincare products powered by its Invisicare® technology and has revolutionized the topical sunscreen market with Skinbrella®, a patented broad-spectrum 80-minute water-resistant sunscreen that meets or exceeds all FDA requirements.

Last year, Skinvisible completed its first international sale of alcohol-free DermSafe® hand sanitizers in China. DermSafe® utilizes a unique formulation that provides a long-lasting protective barrier that binds to the skin for hours and reduces the spread of germs between people and hard surfaces. In September 2017, the company signed a breakthrough exclusive license agreement with Canopy Growth (TSX: WEED) for two distinct cannabis- and hemp-based topical product lines aimed at enhancing penetration of topically used cannabis products.

With 14 patents granted surrounding its novel drug delivery systems and products, it’s little wonder that Quoin Pharmaceuticals looks to merge with Skinvisible. Delivering enhanced and effective non-opioid pain relief is the current Holy Grail of pharmacology, and Skinvisible’s contribution to what may become transformative pain management delivery shouldn’t be underestimated.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Jan 22, 2018 5:21 pm

Skinvisible, Inc. (SKVI) Set to Repeat Olympic Performance in 2018 with DermSafe

- Targeting $80 billion global skincare and dermatology market
- Revenues to be derived from royalties and other licensing fees
- DermSafe sales have taken off in Greater China
- Pending merger will expand product offerings

Among the winners at the 2016 Summer Olympics in Rio was DermSafe® from Skinvisible’s (OTCQB: SKVI) subsidiary, Kintari. Donated to Team Canada, the non-alcohol hand sanitizing lotion offered protection from pathogens to athletes during the Olympic Games. Now, with the Winter Olympics to be held in South Korea from February 8-25, the need is more pressing. Reported outbreaks of the flu have increased dramatically this year, according to the Centers for Disease Control and Prevention (http://nnw.fm/OKg3z). For the first time since it began monitoring flu patterns, the CDC has reported widespread flu activity in every part of the continental U.S. There is no doubt that antiseptics like DermSafe, which inhibit the spread of contact infections, will take center stage again. There’s a lot at stake. Influenza kills at least 12,000 Americans every year.

The main curse this season is the particularly malevolent influenza virus H3N2. It is the most dominant strain not only in the U.S. but in Canada and the UK. The virus, experts believe, is mainly transmitted through the air by droplets formed when infected persons cough, sneeze or talk. These droplets land on hard surfaces like door knobs and as soon as one touches it they have just transferred the virus to their hands. With over 90 percent of all germs coming into one’s body from their hands, it is very important to wash them regularly. Regular use of an alcohol hand sanitizer will work as a replacement to hand washing, but it, too, is only immediate and offers no long term protection. Independent studies verify that DermSafe, when applied to the hands, offers a continuous long term kill on bacteria and viruses tested including the H3N2 virus. Consequently, a hand sanitizer like DermSafe is a vital safeguard against the spread of such germs.

DermSafe incorporates Skinvisible’s proprietary Invisicare® drug delivery technology, which is effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. This allows enhanced delivery performance for a variety of topicals resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

Having made its debut in Rio, DermSafe is set for a repeat performance at the 2018 Winter Olympics in South Korea. Skinvisible has donated over 1,000 bottles of DermSafe to the Canadian Olympic team. DermSafe provides a long-lasting protective barrier that binds to the skin and actively combats the spread of germs between people and between people and hard surfaces. Composed of four percent chlorhexidine gluconate (CHG), the same active ingredient found in soaps used in hospital operating rooms, DermSafe offers long-term protection and destroys both gram-negative and gram-positive bacteria and viruses. It has proven effective against a host of infectious germs, including Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli). Sales of DermSafe have already taken off in China, and the product will be marketed throughout Hong Kong, Macau, Taiwan, Singapore, Malaysia and Thailand.

China, with a population of over 1.6 billion people, exhibits a strong demand for American-made products, driven both by the growth of the middle class in large cities and an increased desire for high quality products. Last year, China imported $2.7 billion in personal care products, and around 69 percent of Chinese women, in one recent survey, said they are in the market for such products and would buy them from online stores, spending an average of $1,800 a year. As well as DermSafe, Kintari offers a line of anti-aging products that includes day cream, night cream, hand and body lotion, and sunscreen. Skinvisible’s foray into Greater China is in line with its strategy of driving Kintari-branded product sales through subsidiaries in the U.S. and Canada and international distribution and licensing agreements.

Along with Skinvisible’s cosmeceutical and over-the-counter products, Skinvisible has signed a letter of intent with Quoin Pharmaceuticals Inc. to merge the two companies and to pursue additional medical conditions, such as post-surgical pain and PTSD with suicidal thoughts in the military.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1314
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Previous

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 2 guests

cron